Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Mouillac

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
The Journal of Biological Chemistry|May 5, 2001
Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptorC Breton, H Chellil, M Kabbaj-Benmansour, et al.
European Journal of Biochemistry|June 24, 2000
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand bindingN Cotte, M N Balestre, A Aumelas, et al.
Advances in Experimental Medicine and Biology|January 1, 1995
Identification of agonist binding sites of vasopressin and oxytocin receptorsB Mouillac, B Chini, M N Balestre, et al.
The EMBO Journal|May 15, 1995
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptorB Chini, B Mouillac, Y Ala, et al.
FEBS Letters|November 18, 1996
Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressinB Chini, B Mouillac, M N Balestre, et al.
Current Opinion in Pharmacology|November 10, 2009
Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processesM Cottet, L Albizu, S Perkovska, et al.
European Journal of Pharmacology|July 23, 1997
Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptorsY Ala, D Morin, E Mahé, et al.
Journal of the American Society of Nephrology : JASN|October 17, 1998
Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotypeY Ala, D Morin, B Mouillac, et al.
British Journal of Pharmacology|February 18, 2014
The Concise Guide to PHARMACOLOGY 2013/14: overviewStephen P H Alexander, Helen E Benson, Elena Faccenda, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
The Journal of Biological Chemistry|May 5, 2001
Direct identification of human oxytocin receptor-binding domains using a photoactivatable cyclic peptide antagonist: comparison with the human V1a vasopressin receptorC Breton, H Chellil, M Kabbaj-Benmansour, et al.
European Journal of Biochemistry|June 24, 2000
Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand bindingN Cotte, M N Balestre, A Aumelas, et al.
Advances in Experimental Medicine and Biology|January 1, 1995
Identification of agonist binding sites of vasopressin and oxytocin receptorsB Mouillac, B Chini, M N Balestre, et al.
The EMBO Journal|May 15, 1995
Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptorB Chini, B Mouillac, Y Ala, et al.
FEBS Letters|November 18, 1996
Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressinB Chini, B Mouillac, M N Balestre, et al.
Current Opinion in Pharmacology|November 10, 2009
Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processesM Cottet, L Albizu, S Perkovska, et al.
European Journal of Pharmacology|July 23, 1997
Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptorsY Ala, D Morin, E Mahé, et al.
Journal of the American Society of Nephrology : JASN|October 17, 1998
Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotypeY Ala, D Morin, B Mouillac, et al.
British Journal of Pharmacology|February 18, 2014
The Concise Guide to PHARMACOLOGY 2013/14: overviewStephen P H Alexander, Helen E Benson, Elena Faccenda, et al.
Pageof 4